Dexcel Pharma has co-led a $60m series A round for Immunai, which previously collected $20m in seed financing less than a year ago.
US-based immunotherapy developer Immunai received $60m in a series A round on Thursday co-led by speciality pharmaceutical firm Dexcel Pharma. Schusterman Family Investments, Duquesne Family Office and Catalio Capital Management co-led the round, which also attracted Viola Ventures and TLV Partners. Founded in 2018, Immunai’s technology combines high-resolution single-cell analytics with machine learning to uncover…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.